Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhat the evidence and the pen mechanics tell you before you decide
Why click charts circulate, and what the pen was actually designed to do
The Wegovy pre-filled pen delivers a single fixed dose per injection. You attach a needle, dial nothing, press the button, and the pen releases the full prescribed amount. That is it. The mechanism was engineered for consistency and safety, not for partial-dose flexibility.
Click charts started circulating in online communities (particularly in the United States, where tirzepatide and semaglutide shortages were acute) as a way of stretching vials or pens. The logic: count audible clicks during injection and stop early to take a fraction of the dose. The problem is that Wegovy's auto-injector pen is not calibrated for that use. The number of clicks audible during an injection varies by pen batch, temperature, injection angle and individual hearing. There is no published validation showing a fixed click count reliably delivers a specific microgram dose from a Wegovy pen. Any chart assigning dose amounts to click counts is, at best, an approximation built on user reports rather than clinical measurement.
If you want to explore what a Wegovy one-click chart involves, the short answer is that the concept comes from the US pen design and does not map cleanly to UK-licensed pens or clinical practice here.
The NHS patient information for semaglutide is clear that doses should be taken as prescribed; partial or modified doses are not described in the licensed instructions. You can read the patient-level overview on the NHS semaglutide medicines page.
The licensed schedule already does what microdosers are trying to do
Most people searching for a microdosing click chart are trying to solve a specific problem: nausea, vomiting, or other gastrointestinal side effects that arrived with the last dose increase. That is a completely legitimate concern. Slow titration is the correct response to it. And the licensed Wegovy schedule is already built around that principle.
The standard schedule moves from 0.25mg to 0.5mg to 1.0mg to 1.7mg to 2.4mg, spending roughly four weeks at each step. The starting dose is not a therapeutic target; its job is to let your digestive system adjust gradually. A prescriber who hears that you are struggling at 0.5mg has legitimate options within the licensed framework: staying at the current dose for longer before stepping up, or temporarily returning to a lower dose. Those options exist, they are documented, and they do not require a click chart.
If you're trying to map your position in the dose ladder, this guide to click dosing and Wegovy covers what different dose levels mean in practice. For the 2.4mg maintenance pen specifically, the 2.4mg click chart question is addressed in its own dedicated page.
The practical check worth doing right now: pull out your current pen and look at the dose window. Confirm it shows the dose your prescriber intended. That single habit catches more errors than any click count.
The clinical risks in modifying a prescribed dose without guidance
Systematically under-dosing a GLP-1 medicine does not simply produce a proportionally smaller effect. Below a certain threshold the appetite-suppression signal weakens substantially. The STEP programme trials, published in the New England Journal of Medicine, used fixed doses across large populations specifically because dose consistency determines outcome consistency. Variability in delivery (the kind introduced by counting clicks) adds noise to that signal.
There is also the question of what happens when side effects are the motivation. Reducing a dose because of nausea without clinical oversight means your prescriber has no record of the adjustment. If symptoms persist or worsen, the clinical picture they are working from is incomplete. Pancreatitis, while uncommon, is a serious possibility the MHRA highlighted in its January 2026 Drug Safety Update for GLP-1 medicines: severe, persistent stomach pain radiating to the back warrants urgent medical attention and is not something to manage by quietly halving a dose at home.
Semaglutide (Wegovy) also carries a Black Triangle (▼) designation, meaning the MHRA requires additional monitoring of reports from real-world use. That monitoring depends on patients and prescribers having an accurate shared picture of what is actually being taken. Diverging from a prescribed dose in an undocumented way disrupts that.
A full overview of how Wegovy works and what clinical supervision looks like in practice is on the Wegovy treatment page. If you've been researching how other injectable weight-loss options compare, the semaglutide and Ozempic comparison clarifies the licensing differences worth knowing.
What to do instead of reaching for a click chart
Contact your prescribing service. That is the direct answer. If side effects are driving the search, tell your prescriber: they can document a dose pause, a step-back, or a longer time at the current level. If supply is the issue (a pen that has not arrived, a dose you need to make last) tell them that too. Good clinical services account for these situations without requiring you to experiment with pen mechanics.
At nume, prescribers review your case before every repeat order. A real clinician reads your update (not automated software) and dose decisions are made in that context, with your full picture in front of them. The question of how many clicks constitute a microdose is one our clinical team hears, and the consistent answer is: bring that question to us rather than a chart, because the answer depends on what is driving it.
If you are considering starting treatment or are weighing up your options, speak to our prescribers, the consultation is free, and the clinical review happens the same day.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.